Stockscreener 앱 받기
3.32
2.64%
-0.09
전일 마감가:
$3.41
열려 있는:
$3.41
하루 거래량:
136.37K
Relative Volume:
1.49
시가총액:
$28.89M
수익:
-
순이익/손실:
$-4.69M
주가수익비율:
-1.4249
EPS:
-2.33
순현금흐름:
$-3.81M
1주 성능:
-9.04%
1개월 성능:
-19.02%
6개월 성능:
-10.75%
1년 성능:
+37.76%
1일 변동 폭
$3.32
$3.64
1주일 범위
$3.2647
$3.66
52주 변동 폭
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
명칭
Lixte Biotechnology Holdings Inc
전화
310 203 2902
주소
433 PLAZA REAL, BOCA RATON
LIXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.32 | 29.68M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lixte Biotechnology Holdings Inc 주식(LIXT)의 최신 뉴스
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Aug Movers: Is OPAD a play on infrastructure spending2025 Trade Ideas & Expert Approved Trade Ideas - baoquankhu1.vn
Institution Moves: How Lixte Biotechnology Holdings Inc stock performs after earningsJuly 2025 Market Mood & Low Volatility Stock Suggestions - Bộ Nội Vụ
LIXTE Biotechnology Engages IBN to Amplify Communications for Cancer Therapy Development - citybuzz -
Pittsburgh Post-Gazette - FinancialContent
LIXTE Biotechnology (LIXT) Enhances Visibility with New Communications Strategy - GuruFocus
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc. - The Manila Times
Breakout Zone: Can Lixte Biotechnology Holdings Inc Equity Warrant withstand a market correctionPortfolio Gains Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Weekly Trades: How Lixte Biotechnology Holdings Inc stock compares to growth peersEarnings Performance Report & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuationTreasury Yields & Expert-Curated Trade Recommendations - Улправда
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit & Smart Swing Trading Techniques - Улправда
How Lixte Biotechnology Holdings Inc. stock compares to growth peers2025 Biggest Moves & Technical Entry and Exit Tips - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesPortfolio Return Summary & Entry and Exit Point Strategies - Улправда
Should I hold or sell Lixte Biotechnology Holdings Inc. stock in 2025Weekly Investment Summary & Accurate Technical Buy Alerts - Улправда
Can Lixte Biotechnology Holdings Inc. (8640) stock ride next bull market cycleQuarterly Market Review & Technical Buy Zone Confirmation - Улправда
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - NewMediaWire
Will Lixte Biotechnology Holdings Inc. (8640) stock beat revenue estimatesFed Meeting & Low Risk Entry Point Tips - Улправда
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Lixte Biotechnology Expands Ovarian Cancer Trial with MD Anderson and GSK - citybuzz -
Will Lixte Biotechnology Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & AI Driven Stock Reports - ulpravda.ru
Lixte Biotechnology files to sell 5.26M shares of common stock, warrants - MSN
How strong is Lixte Biotechnology Holdings Inc. Equity Warrant stock revenue growth2025 Trade Ideas & Entry Point Strategy Guides - Улправда
Lixte Biotechnology announces new registered direct offering - MSN
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - financial-news.co.uk
Breakout Zone: Why Lixte Biotechnology Holdings Inc. stock is a value investor pickJuly 2025 Weekly Recap & Real-Time Market Sentiment Reports - Улправда
About Us - FinancialContent
Can Lixte Biotechnology Holdings Inc. stock continue upward trendEarnings Forecast Updates & High Yield Trading Growth - ulpravda.ru
Lixte Biotechnology Holdings (NASDAQ: LIXT) Announces $4.3M Registered Direct Offering Priced at Market - Digital Journal
LIXTE Biotechnology Advances Novel Cancer Treatment Platform Through Clinical Trials and Strategic Moves - citybuzz -
Lixte Biotechnology Holdings Secures $4.3 Million in Registered Direct Offering to Advance Cancer Drug Development - citybuzz -
About Us | Oil & Gas JournalLIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’ - FinancialContent
WaterWorldLIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’ - FinancialContent
Will Lixte Biotechnology Holdings Inc. (8640) stock deliver compounding returns2026 world cup usa national team quarterfinals young talents transition play winner prediction breakdown - Улправда
Aug Decliners: Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendationsInsider Buying & Weekly Momentum Stock Picks - Bộ Nội Vụ
What analysts say about Lixte Biotechnology Holdings Inc 8640 stockCandlestick Trading Patterns & High Return Stock Picks - earlytimes.in
What analysts say about SBCWW stockTechnical Breakout Signals & Free Wealth Planning Blueprints - earlytimes.in
Should You Add Aster DM Healthcare Limited Stock to Your Portfolio NowResistance Breakout Alerts & Minimal Capital Growth - earlytimes.in
Lixte Simplifies Capital Structure via Share Exchange Deal - TipRanks
Price Clustering Detected in Anupam Finserv Limited StockLong-Term Investment Plans & Low Risk High Yield - bollywoodhelpline.com
LIXTE expands clinical trial for ovarian cancer treatment By Investing.com - Investing.com Australia
Lixte Expands LB-100 Ovarian Cancer Trial Collaboration - TipRanks
Lixte expands LB-100 ovarian cancer trial collaboration - MSN
Key facts: Lixte Biotechnology secures $4.3M funding; expands cancer collaboration - TradingView — Track All Markets
LIXTE expands clinical trial for ovarian cancer treatment - Investing.com
Lixte Biotechnology Holdings expands collaboration with University of Texas MD Anderson Cancer Center & GSK for LB-100 - marketscreener.com
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - InvestorNews
Experimental ovarian cancer trial doubles the number of patients it will enroll - Stock Titan
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering - Investing.com Nigeria
Lixte Biotechnology Announces New Registered Direct Offering - TipRanks
Lixte Biotechnology Signs Multiple Material Agreements - TradingView — Track All Markets
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering By Investing.com - Investing.com South Africa
Lixte Biotechnology Holdings Inc (LIXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):